BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
On Tuesday, UBS reiterated its Buy rating and $180.00 price target for Johnson & Johnson (NYSE:JNJ) stock. The firm’s analyst noted the recent legal developments regarding the company’s ongoing talc-related lawsuits. A federal judge has dismissed Johnson & Johnson’s third attempt to settle these cases through bankruptcy. This decision represents a challenge for the company in finding a resolution for the numerous lawsuits it faces.
Johnson & Johnson management had previously indicated that if their bankruptcy strategy were denied, they would consider other options, which could include returning to the traditional tort litigation system to contest the lawsuits. The company has experienced some victories in court, which may provide a degree of optimism for their potential success with this approach.
The analyst from UBS acknowledged that while further details are expected from Johnson & Johnson, the current uncertainty regarding the timing of a final resolution could continue to affect the company’s stock performance. Despite this setback, the firm’s position on the stock remains unchanged, with a positive outlook reflected in the maintained Buy rating and price target.
In other recent news, Johnson & Johnson’s financial and legal landscape has seen significant developments. A U.S. bankruptcy judge has rejected the company’s $10 billion proposal to resolve lawsuits related to claims that its talc products cause ovarian cancer. This marks the third failed attempt by Johnson & Johnson to use bankruptcy as a strategy to settle these claims. Additionally, a unit of Johnson & Johnson has been ordered to pay $1.64 billion to the U.S. government after being found guilty of unlawfully promoting HIV drugs, according to a federal judge’s ruling.
On the medical front, Johnson & Johnson reported promising results from its Phase 3 MARIPOSA study, indicating that the combination of RYBREVANT® and LAZCLUZE™ significantly extended survival in patients with advanced non-small cell lung cancer. The company also presented new data on nipocalimab’s efficacy in treating generalized myasthenia gravis, demonstrating significant improvement in muscle strength among patients. These medical advancements were shared at major conferences, highlighting the company’s ongoing research efforts.
In terms of analyst activity, recent legal and medical updates have not led to any reported upgrades or downgrades from major analyst firms. Johnson & Johnson’s efforts in expanding treatment options and addressing legal challenges continue to be focal points for investors. These developments underscore the company’s ongoing commitment to resolving legal issues while advancing its medical research and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.